Literature DB >> 23704208

c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.

Ping Fan1, Obi L Griffith, Fadeke A Agboke, Pavana Anur, Xiaojun Zou, Russell E McDaniel, Karen Creswell, Sung Hoon Kim, John A Katzenellenbogen, Joe W Gray, V Craig Jordan.   

Abstract

The emergence of anti-estrogen resistance in breast cancer is an important clinical phenomenon affecting long-term survival in this disease. Identifying factors that convey cell survival in this setting may guide improvements in treatment. Estrogen (E2) can induce apoptosis in breast cancer cells that have been selected for survival after E2 deprivation for long periods (MCF-7:5C cells), but the mechanisms underlying E2-induced stress in this setting have not been elucidated. Here, we report that the c-Src kinase functions as a key adapter protein for the estrogen receptor (ER, ESR1) in its activation of stress responses induced by E2 in MCF-7:5C cells. E2 elevated phosphorylation of c-Src, which was blocked by 4-hydroxytamoxifen (4-OHT), suggesting that E2 activated c-Src through the ER. We found that E2 activated the sensors of the unfolded protein response (UPR), IRE1α (ERN1) and PERK kinase (EIF2AK3), the latter of which phosphorylates eukaryotic translation initiation factor-2α (eIF2α). E2 also dramatically increased reactive oxygen species production and upregulated expression of heme oxygenase HO-1 (HMOX1), an indicator of oxidative stress, along with the central energy sensor kinase AMPK (PRKAA2). Pharmacologic or RNA interference-mediated inhibition of c-Src abolished the phosphorylation of eIF2α and AMPK, blocked E2-induced ROS production, and inhibited E2-induced apoptosis. Together, our results establish that c-Src kinase mediates stresses generated by E2 in long-term E2-deprived cells that trigger apoptosis. This work offers a mechanistic rationale for a new approach in the treatment of endocrine-resistant breast cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23704208      PMCID: PMC3715569          DOI: 10.1158/0008-5472.CAN-12-4152

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta.

Authors:  T Nakagawa; H Zhu; N Morishima; E Li; J Xu; B A Yankner; J Yuan
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

Review 2.  Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.

Authors:  R J Santen; R X Song; Z Zhang; R Kumar; M-H Jeng; S Masamura; J Lawrence; L P MacMahon; W Yue; L Berstein
Journal:  J Steroid Biochem Mol Biol       Date:  2005-05       Impact factor: 4.292

3.  AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes.

Authors:  Yossi Dagon; Yosefa Avraham; Elliot M Berry
Journal:  Biochem Biophys Res Commun       Date:  2005-12-06       Impact factor: 3.575

4.  Activating AMP-activated protein kinase without AMP.

Authors:  Morris J Birnbaum
Journal:  Mol Cell       Date:  2005-08-05       Impact factor: 17.970

Review 5.  Organelle-specific initiation of cell death pathways.

Authors:  K F Ferri; G Kroemer
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

6.  A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

Authors:  Houda Jallal; Maria-Luisa Valentino; Gaoping Chen; Frank Boschelli; Suhad Ali; Shafaat A Rabbani
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

7.  Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.

Authors:  Clodia Osipo; Csaba Gajdos; Hong Liu; Bin Chen; V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2003-11-05       Impact factor: 13.506

8.  An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

Authors:  S Y Jiang; D M Wolf; J M Yingling; C Chang; V C Jordan
Journal:  Mol Cell Endocrinol       Date:  1992-12       Impact factor: 4.102

9.  Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.

Authors:  Gauri Sabnis; Adam Schayowitz; Olga Goloubeva; Luciana Macedo; Angela Brodie
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

10.  Heme oxygenase-1, oxidation, inflammation, and atherosclerosis.

Authors:  Jesus A Araujo; Min Zhang; Fen Yin
Journal:  Front Pharmacol       Date:  2012-07-19       Impact factor: 5.810

View more
  44 in total

1.  Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

2.  Avoiding the bad and enhancing the good of soy supplements in breast cancer.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-04       Impact factor: 13.506

3.  Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.

Authors:  V Craig Jordan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

4.  Src couples estrogen receptor to the anticipatory unfolded protein response and regulates cancer cell fate under stress.

Authors:  Liqun Yu; Lawrence Wang; Ji Eun Kim; Chengjian Mao; David J Shapiro
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-06-02       Impact factor: 4.739

5.  Estrogen-induced epigenetic silencing of FTH1 and TFRC genes reduces liver cancer cell growth and survival.

Authors:  Jibran Sualeh Muhammad; Khuloud Bajbouj; Jasmin Shafarin; Mawieh Hamad
Journal:  Epigenetics       Date:  2020-06-01       Impact factor: 4.528

6.  Ligand Accessibility and Bioactivity of a Hormone-Dendrimer Conjugate Depend on pH and pH History.

Authors:  Sung Hoon Kim; Zeynep Madak-Erdogan; Sung Chul Bae; Kathryn E Carlson; Christopher G Mayne; Steve Granick; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Am Chem Soc       Date:  2015-08-10       Impact factor: 15.419

Review 7.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

8.  Suppression of Nuclear Factor-κB by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.

Authors:  Ping Fan; Doris R Siwak; Balkees Abderrahman; Fadeke A Agboke; Smitha Yerrum; V Craig Jordan
Journal:  Mol Cancer Ther       Date:  2019-09-11       Impact factor: 6.261

9.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.